Sanofi (EPA:SAN)
France · Delayed Price · Currency is EUR 84.84
-0.94 (-1.10%)
Oct 7, 2025, 5:35 PM CET
Sanofi Revenue
Sanofi had revenue of 10.74B EUR in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to 45.74B, up 15.65% year-over-year. In the year 2024, Sanofi had annual revenue of 44.29B with 7.73% growth.
Revenue (ttm)
45.74B
Revenue Growth
+15.65%
P/S Ratio
2.26
Revenue / Employee
551.87K
Employees
82,878
Market Cap
103.23B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 44.29B | 3.18B | 7.73% |
| Dec 31, 2023 | 41.11B | 805.00M | 2.00% |
| Dec 31, 2022 | 40.30B | 1.13B | 2.88% |
| Dec 31, 2021 | 39.18B | 1.81B | 4.83% |
| Dec 31, 2020 | 37.37B | -262.00M | -0.70% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EssilorLuxottica Société anonyme | 27.24B |
| Sartorius Stedim Biotech | 2.90B |
| bioMérieux | 4.12B |
| Eurofins Scientific SE | 7.14B |
| Ipsen | 3.76B |
| ABIVAX Société Anonyme | 6.02M |
| Virbac | 1.43B |
| emeis Société anonyme | 5.77B |
Sanofi News
- 9 hours ago - Novavax (NVAX) Transfers EU Vaccine Rights to Sanofi for $25M - GuruFocus
- 11 hours ago - Novavax hands over Nuvaxovid marketing rights to Sanofi in the EU - Seeking Alpha
- 12 hours ago - Sanofi (SNY) Gains Full EU Control of Nuvaxovid from Novavax - GuruFocus
- 1 day ago - AstraZeneca Taps Gene Editing And AI Platform For Drug Discovery For Immunology Diseases - Benzinga
- 2 days ago - Sanofi: Undervalued 2026 Pipeline, And Solid Results (Rating Upgrade) - Seeking Alpha
- 4 days ago - Bullish Two Hundred Day Moving Average Cross - SNY - Nasdaq
- 5 days ago - Sanofi (SNY) Supports Revvity's Expansion in Type 1 Diabetes Assay - GuruFocus
- 5 days ago - Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes - Business Wire